2021 Annual Meeting Startup & Practice Management Access Pass-Treatment of human bone marrow concentrate and bone marrow stem cells with senolytic agents

Treatment of human bone marrow concentrate and bone marrow stem cells with senolytic agents

Video Transcription

Video Summary

Katie Whitney, an MPH epidemiology student and research specialist at CU Anschutz, discusses innovative methods to enhance bone marrow aspirate concentrate (BMAC) and bone marrow-derived stem cell function. Post-traumatic osteoarthritis incidence is rising, especially in young adults, partly due to cellular senescence that reduces tissue regenerative capacity. Her research investigates the role of senescent cells and their secretory factors (SASP) in musculoskeletal decline, using a senolytic agent, fisetin, to target and remove these cells. Whitney's lab employs a novel autofluorescent marker, C12 FDG, to detect senescence in bone marrow and peripheral blood. Two ongoing federally funded clinical trials assess fisetin’s effect on symptomatic knee osteoarthritis alone and combined with BMAC. The goal is to improve cell function by reducing senescence and SASP, potentially delaying osteoarthritis progression. The study also aims to establish normative senescence levels across ages and evaluate gene expressions involved in cell cycle arrest, contributing to better therapeutic strategies for musculoskeletal healing and healthy aging.

Asset Caption

Dr. Kaitie Whitney

Keywords

bone marrow aspirate concentrate

cellular senescence

senolytic agent fisetin

post-traumatic osteoarthritis

autofluorescent marker C12 FDG